Altered gene expression underlies impaired function of brain areas regulating vision and motor control, which may be associated with behavioral issues in people with Prader-Willi syndrome (PWS) and other disorders, a study suggests. The study, “Central neurogenetic signatures of the visuomotor integration system,” was published…
Lipidio Pharmaceuticals has completed the first step of financing to support its development of GDD3898, a treatment candidate for Prader Willi syndrome (PWS) and other conditions associated with obesity. Investors in this series A funding include the Foundation for Prader Willi Research. “Prader-Willi syndrome, or PWS,…
Harmony Biosciences has kicked off a Phase 2 clinical trial to evaluate the safety and effectiveness of pitolisant to treat excessive daytime sleepiness in people with Prader-Willi syndrome, ages 6 to 65. The study (NCT04257929) is expected to start enrolling participants soon, the company said in a…
Get regular updates to your inbox.
